---
layout: default
title: Tioconazole
description: "Tioconazole 的老藥新用潛力分析。模型預測等級 L5，包含 3 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 175
evidence_level: L1
indication_count: 3
---

# Tioconazole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>3</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tioconazole (治可那唑) - 藥師評估報告

## 一句話總結

<p class="key-answer" data-question="Tioconazole 可以用於治療什麼新適應症？">
Tioconazole 是一種咪唑類抗黴菌藥物，TxGNN 預測其用於外陰陰道炎獲得豐富臨床試驗與文獻支持，實際上這已是其核准適應症的延伸應用。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥物名稱 | Tioconazole (治可那唑) |
| DrugBank ID | DB01007 |
| 原適應症 | 感受性黴菌引起之局部感染症 |
| 預測新適應症 | vulvovaginal candidiasis、vulvovaginitis、vulvitis |
| TxGNN 分數 | 0.992 (排名 13,733) |
| 證據等級 | 2 項臨床試驗、20+ 篇相關文獻 |
| 台灣上市狀態 | 有效許可證（妥舒乳膏等） |

---





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. vulvovaginitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.23%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 機轉分析</p>

<p>Tioconazole 是廣效咪唑類抗黴菌藥物，其作用機轉為抑制真菌細胞膜麥角固醇合成。預測用於外陰陰道炎完全符合其藥理特性：</p>

<ol>
<li><strong>抗念珠菌活性</strong>：對 Candida albicans 及其他念珠菌屬具高度活性</li>
<li><strong>抗滴蟲活性</strong>：對 Trichomonas vaginalis 也有一定效果</li>
<li><strong>局部應用優勢</strong>：陰道製劑可達到高局部濃度，全身吸收少</li>
</ol>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03839875" target="_blank">NCT03839875</a></td><td>PHASE4</td><td>COMPLETED</td><td>116</td><td>A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Ef...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06056947" target="_blank">NCT06056947</a></td><td>PHASE3</td><td>COMPLETED</td><td>577</td><td>Phase III Study to Evaluate Efficacy and Safety of Different Formulations of Fen...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3510114/" target="_blank">3510114</a></td><td>1986</td><td>Article</td><td>Drugs</td><td>Tioconazole. A review of its antimicrobial activity and therapeutic use in super...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40464716/" target="_blank">40464716</a></td><td>2025</td><td>Article</td><td>Expert review of anti-infectiv</td><td>The future of non-invasive azole antifungal treatment options for the management...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10470518/" target="_blank">10470518</a></td><td>1999</td><td>Article</td><td>Comprehensive therapy</td><td>Vulvovaginitis in healthy women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34550113/" target="_blank">34550113</a></td><td>2021</td><td>Article</td><td>The Medical letter on drugs an</td><td>Ibrexafungerp (Brexafemme) for vulvovaginal candidiasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873744/" target="_blank">6873744</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole cream and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3524439/" target="_blank">3524439</a></td><td>1986</td><td>Article</td><td>Antimicrobial agents and chemo</td><td>Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovagin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6347833/" target="_blank">6347833</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Double-blind comparison of the efficacy, tolerance and safety of tioconazole and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6347834/" target="_blank">6347834</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole and econaz...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30553009/" target="_blank">30553009</a></td><td>2019</td><td>Article</td><td>International journal of pharm</td><td>Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternativ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4025721/" target="_blank">4025721</a></td><td>1985</td><td>Article</td><td>The Alabama journal of medical</td><td>The clinical and cytological assessment of tioconazole in vulvo-vaginal candidia...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34286728/" target="_blank">34286728</a></td><td>2021</td><td>Article</td><td>Analytical methods : advancing</td><td>Quantitative and specific detection of viable pathogens on a portable microfluid...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873745/" target="_blank">6873745</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole cream used...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873743/" target="_blank">6873743</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open studies of the efficacy, tolerance, systemic absorption and vaginal persist...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10990271/" target="_blank">10990271</a></td><td>2000</td><td>Article</td><td>Microbial drug resistance (Lar</td><td>Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3895961/" target="_blank">3895961</a></td><td>1985</td><td>Article</td><td>American journal of obstetrics</td><td>Is more than one application of an antifungal necessary in the treatment of acut...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6094282/" target="_blank">6094282</a></td><td>1984</td><td>Article</td><td>The Journal of international m</td><td>Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3216880/" target="_blank">3216880</a></td><td>1988</td><td>Article</td><td>Mycoses</td><td>Tioconazole in the treatment of vaginal candidosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3984688/" target="_blank">3984688</a></td><td>1985</td><td>Article</td><td>Acta obstetricia et gynecologi</td><td>Treatment of vaginal candidosis with tioconazole 2% vaginal cream.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873747/" target="_blank">6873747</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Tioconazole in the treatment of vaginal candidiasis. An international clinical r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6683696/" target="_blank">6683696</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. vulvitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03839875" target="_blank">NCT03839875</a></td><td>PHASE4</td><td>COMPLETED</td><td>116</td><td>A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Ef...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06056947" target="_blank">NCT06056947</a></td><td>PHASE3</td><td>COMPLETED</td><td>577</td><td>Phase III Study to Evaluate Efficacy and Safety of Different Formulations of Fen...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3510114/" target="_blank">3510114</a></td><td>1986</td><td>Article</td><td>Drugs</td><td>Tioconazole. A review of its antimicrobial activity and therapeutic use in super...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40464716/" target="_blank">40464716</a></td><td>2025</td><td>Article</td><td>Expert review of anti-infectiv</td><td>The future of non-invasive azole antifungal treatment options for the management...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10470518/" target="_blank">10470518</a></td><td>1999</td><td>Article</td><td>Comprehensive therapy</td><td>Vulvovaginitis in healthy women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34550113/" target="_blank">34550113</a></td><td>2021</td><td>Article</td><td>The Medical letter on drugs an</td><td>Ibrexafungerp (Brexafemme) for vulvovaginal candidiasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873744/" target="_blank">6873744</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole cream and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3524439/" target="_blank">3524439</a></td><td>1986</td><td>Article</td><td>Antimicrobial agents and chemo</td><td>Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovagin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6347833/" target="_blank">6347833</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Double-blind comparison of the efficacy, tolerance and safety of tioconazole and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6347834/" target="_blank">6347834</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole and econaz...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30553009/" target="_blank">30553009</a></td><td>2019</td><td>Article</td><td>International journal of pharm</td><td>Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternativ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4025721/" target="_blank">4025721</a></td><td>1985</td><td>Article</td><td>The Alabama journal of medical</td><td>The clinical and cytological assessment of tioconazole in vulvo-vaginal candidia...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873745/" target="_blank">6873745</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open comparison of the efficacy, toleration and safety of tioconazole cream used...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873743/" target="_blank">6873743</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Open studies of the efficacy, tolerance, systemic absorption and vaginal persist...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10990271/" target="_blank">10990271</a></td><td>2000</td><td>Article</td><td>Microbial drug resistance (Lar</td><td>Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3895961/" target="_blank">3895961</a></td><td>1985</td><td>Article</td><td>American journal of obstetrics</td><td>Is more than one application of an antifungal necessary in the treatment of acut...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3216880/" target="_blank">3216880</a></td><td>1988</td><td>Article</td><td>Mycoses</td><td>Tioconazole in the treatment of vaginal candidosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6094282/" target="_blank">6094282</a></td><td>1984</td><td>Article</td><td>The Journal of international m</td><td>Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3984688/" target="_blank">3984688</a></td><td>1985</td><td>Article</td><td>Acta obstetricia et gynecologi</td><td>Treatment of vaginal candidosis with tioconazole 2% vaginal cream.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1951575/" target="_blank">1951575</a></td><td>1991</td><td>Article</td><td>American journal of obstetrics</td><td>The in vitro activity of terconazole against yeasts: its topical long-acting the...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6873747/" target="_blank">6873747</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Tioconazole in the treatment of vaginal candidiasis. An international clinical r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6683696/" target="_blank">6683696</a></td><td>1983</td><td>Article</td><td>Gynakologische Rundschau</td><td>Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. postmenopausal atrophic vaginitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市情形

Tioconazole 在台灣有外用製劑許可證：

| 許可證字號 | 品名 | 劑型 | 適應症 |
|-----------|------|------|--------|
| 有效許可證 | 妥舒乳膏 1% | 乳膏劑 | 感受性黴菌引起之局部感染 |

**注意**：台灣目前無陰道專用製劑，如需用於外陰陰道炎，需使用現有外用乳膏。

---

## 安全性考量

### 藥物交互作用

Tioconazole 為局部用藥，全身吸收極少，藥物交互作用風險低。

### 常見不良反應

1. 局部刺激感、搔癢（發生率約 5-30%）
2. 燒灼感
3. 紅疹

### 使用注意事項

1. 月經期間應避免使用陰道製劑
2. 可能損壞乳膠保險套與子宮帽
3. 如 3 天後症狀未改善應就醫

---

## 結論

### 預測適應症評估

| 適應症 | TxGNN 分數 | 臨床試驗 | 文獻 | 建議 |
|-------|-----------|---------|------|------|
| 外陰陰道炎 | 0.992 | 2 項 | 20+ 篇 | **建議（證據充足）** |

### 臨床建議

1. **念珠菌性外陰陰道炎**：Tioconazole 是有效的治療選擇
   - 國際上有單劑量 6.5% 陰道軟膏製劑
   - 療效與 Clotrimazole、Miconazole 相當

2. **台灣使用考量**：
   - 目前僅有外用乳膏劑型
   - 若需治療外陰陰道炎，可考慮其他有陰道製劑的咪唑類藥物

3. **優勢**：
   - 可單劑量治療
   - 局部用藥全身副作用少
   - 對多數念珠菌菌株有效

---

*報告產生日期：2026-02-11*
*資料來源：TxGNN 知識圖譜預測、ClinicalTrials.gov、PubMed、台灣 FDA*


---

## 相關藥物報告

- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - 證據等級 L5
- [Remdesivir]({{ "/drugs/remdesivir/" | relative_url }}) - 證據等級 L5
- [Travoprost]({{ "/drugs/travoprost/" | relative_url }}) - 證據等級 L5
- [Nebivolol]({{ "/drugs/nebivolol/" | relative_url }}) - 證據等級 L5
- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Tioconazole老藥新用驗證報告. https://twtxgnn.yao.care/drugs/tioconazole/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_tioconazole,
  title = {Tioconazole老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tioconazole/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
